CCS
ABMD

Crosspoint Capital Strategies’s Abiomed Inc ABMD Stock Holding History

Crosspoint Capital Strategies’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-81
Closed -$6K – 658
2015
Q1 		$6K Buy
+81
New +$4.4K ﹤0.01% 433

Other funds holding ABMD

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
1832 Asset Management
1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return

Crosspoint Capital Strategies's ABMD Position: Q2 2015 in Review

Crosspoint Capital Strategies sold out of Abiomed Inc (ABMD) in Q2 2015, closing a stake of 81 shares — an estimated $6K sold.

Crosspoint Capital Strategies first reported a position in ABMD in Q1 2015 and held it in 1 quarter. The position peaked at $6K in Q1 2015. 227 funds tracked by Wall St. Rank hold ABMD as of Q2 2015.

  • Crosspoint Capital Strategies reported no remaining Abiomed Inc position as of Q2 2015 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 81 Abiomed Inc shares in Q2 2015, an estimated $6K.
  • Crosspoint Capital Strategies first reported a position in Abiomed Inc in Q1 2015 and held it in 1 quarter.
  • Crosspoint Capital Strategies's Abiomed Inc position peaked at $6K in Q1 2015.
  • 227 funds tracked by Wall St. Rank held Abiomed Inc as of Q2 2015.

Based on Crosspoint Capital Strategies's 13F filing for Q2 2015, filed 24 Aug 2015.